CompletedPhase 2

Use of N-Acetylcysteine During Liver Procurement

Italy140 participantsStarted 2006-12

Plain-language summary

Randomized prospective study on the impact on the post-LT outcome by the infusion of N-acetylcysteine (NAC) during the liver procurement procedure, as an anti-oxidant agent to reduce the ischemia-reperfusion damage of organs for liver transplantation (LT).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * all consecutive subjects with chronic liver disease undergoing first Liver Transplantation receiving deceased donor livers Exclusion Criteria: * recipients with acute liver disease; * paediatric patients or adult patients receiving a liver from a paediatric donor; * patients undergoing multiple-organ transplantation; * patients undergoing re-transplantation of the Liver; * patients undergoing living donor Liver Transplantation

What they're measuring

Graft survival

Timeframe: up to 60 months

Trial details

NCT IDNCT01394497

SponsorAzienda Ospedaliera di Padova

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2009-07

View on ClinicalTrials.gov More Liver Failure trials